SOLID TUMOR

This early-phase study tested a new drug (S095029) alone and with another drug (Sym021) in 41 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was stopped early for business …

This study tested a drug called utidelone in 126 people with advanced solid tumors (like stomach, pancreatic, or ovarian cancer) that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors and how safe it was. Results will help decide if la…

This early-phase study tested the safety of combining several cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 people with advanced or metastatic solid tumors. The goal was to find safe doses for each combination to use in later studies. Participant…

This early-phase study tested a new drug called LP-118 in 68 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find a safe dose and see how the body processes the drug. LP-118 works by blocking certain proteins that…

This early-stage trial tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) whose solid tumors, brain tumors, or lymphoma had stopped responding to standard treatments. The main goal was to find the safest dose and identify side effects. Researchers also …

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug is safe and to find the best dose. Researchers also looked for early signs that the drug might shrink tu…

This early-phase study tested a new drug called FS1502 in 161 adults with advanced solid tumors that express HER2, including HER2+ breast cancer. The goal was to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants had already tried other treat…

This study tested a new drug combination (MK-4280A) in 163 people with either a type of skin cancer (cutaneous squamous cell carcinoma) or endometrial cancer. The goal was to see if the treatment could shrink or eliminate tumors. Participants received either the new combination o…

This study tested a precise type of radiation called proton beam therapy to treat liver tumors that have spread from other cancers. 92 adults with 1 to 4 liver tumors received this targeted treatment. The goal was to see if it could stop tumor growth and cause fewer side effects …

This early-phase study tested a new drug called TPST-1495, alone or with pembrolizumab, in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancer) that had stopped responding to standard treatments. The main goal was to find the safest dose and check…

This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while also boosting the immune system. The main goal was to check safety and…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with pembrolizumab, in 182 adults with advanced solid tumors (including lung and triple-negative breast cancers). The main goal was to check safety and how the drug moves through the b…

This early-stage trial tested two experimental drugs, BNT152 and BNT153, in 86 adults with advanced solid tumors that had spread or could not be removed and had no standard treatment options. The main goal was to check safety and find the best dose. Researchers also looked for si…

This study tested a combination of three drugs (afuresertib, sintilimab, and chemotherapy) in 22 adults with solid tumors like lung, cervical, or stomach cancer that had stopped responding to prior immunotherapy. The goal was to find the safest dose and see if the combo could shr…

This early-phase study tested a new immune cell treatment called PD-L1 t-haNK in 16 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to check the treatment's safety, find the best dose, and see if it could shrink tumors. Th…

This early study tested a new treatment called QH104 for people with solid tumors that have spread to the lining of the brain (meningeal metastases). The treatment uses specially engineered immune cells (CAR-γδ T cells) injected directly into the fluid around the brain. The goal …

This early-phase study tested a new drug called SAIL66 in 22 adults with advanced solid tumors that have a specific protein (CLDN6). The main goals were to check safety, find the right dose, and see if the drug can shrink tumors. Participants received the drug by infusion, and re…

This early-phase study tested the safety of a new antibody drug called HH-101 in 12 adults with advanced solid tumors that had not responded to other treatments. The main goal was to see what side effects occurred and find a safe dose. Researchers also looked for early signs that…

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and check for side effects, while also looking at how the drug moves through…

This study tested whether combining several immunotherapy drugs could help people with advanced prostate cancer that no longer responds to hormone therapy. 59 adults received one of three drug combinations. The goal was to see if the treatments could shrink tumors or lower PSA le…

This early-phase study tested an experimental drug called RC108-ADC in 67 adults with advanced solid tumors that have a specific protein (c-Met). The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. Participants received the drug by injecti…

This early-phase study tested a new drug called HCW9218 in 18 people with advanced solid tumors that had not responded to at least two prior treatments. The drug works by activating immune cells and blocking signals that help tumors grow. The main goal was to find a safe dose and…

This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients whose advanced solid tumors had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. While the treatment aims to…

This early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with solid tumors. The main goals were to check safety, find the best dose, and see if the drug can shrink tumors. Participants took the drug alone, and researchers monitored side effects and tumor …

This early-phase study tested an experimental drug called JAB-BX102, given alone or with pembrolizumab, in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for …

This study tested a new drug, IBI129, in 180 adults with advanced solid tumors that couldn't be removed by surgery. The goal was to find the safest dose and see if the drug can shrink tumors. It was an early-phase trial to gather information on safety and effectiveness.

This study tested a new drug, ALRN-6924, in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments. The study found the dru…

This early-phase trial tested a new radioactive imaging agent called 68Ga-NOTA-SNA002 in 17 adults with solid tumors. The goal was to check if it is safe and how it spreads in the body during PET scans. Researchers measured vital signs, lab results, and side effects to understand…

This study tested whether a smartphone app helps cancer patients take their oral medications more consistently than a traditional paper diary. A total of 124 adults with solid tumors or blood cancers were randomly assigned to use either an electronic diary or a paper diary to tra…

This study looked at how healthy men absorb, process, and eliminate a single dose of the experimental cancer drug IMP4297. Six volunteers took a radioactive-labeled pill, and researchers measured the drug in blood, urine, and stool over time. The goal was to understand the drug's…

This study tested whether a 10 mg and a 20 mg capsule of the experimental drug IMP4297 are processed similarly by the body. It involved 28 healthy Chinese adults who took a single dose of each strength on separate days. The goal was to check bioequivalence, not to treat any disea…

This study tested two different strengths (10 mg and 20 mg) of an experimental drug called IMP4297 in 36 healthy Chinese men. The goal was to see if the body processes both strengths the same way after a meal. This is a bioequivalence study, meaning it checks if the two versions …

This study looked at how common frailty is among people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also checked whether the test results matched the docto…

This pilot study tested whether doctors can safely adjust proton radiation therapy plans while the patient is still on the treatment table. Ten adults with solid tumors participated. The goal was to see if this real-time adjustment is practical and safe enough to study in a large…

This study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in 154 patients during routine blood tests. They also checked if mus…

This study looked at how the experimental drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received the drug by mouth and by IV with a tiny radioactive marker to track it. The main goal was to understand the…

This study followed 150 adults with solid tumors who were starting immunotherapy. Researchers collected data on side effects and quality of life during routine treatment. The goal was to better understand how and when side effects occur, helping doctors manage them more effective…